BMAL1 and hepatocellular carcinoma: In hepatocellular carcinoma, the treatment of insulin-like growth factor 1 promoted CK2-mediated CLOCK S106 phosphorylation, which consequentially disrupts the CLOCK-BMAL1 heterodimer and suppresses the expression of its downstream genes [17].